Eli Lilly Jun 13, 2026 Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting - investor.lilly.com
Eli Lilly Jun 13, 2026 Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’ - Fierce Biotech
Eli Lilly Jun 13, 2026 Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting - PR Newswire
Eli Lilly Jun 13, 2026 Abridge partners with Eli Lilly, Nvidia as AI scribe eyes expansion - Healthcare Dive
Eli Lilly Jun 11, 2026 Abridge picks up strategic investment from Eli Lilly, expands payer, research workflows - Fierce Healthcare
Eli Lilly Jun 8, 2026 With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race - Fierce Pharma
Eli Lilly Jun 8, 2026 ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option - BioPharma Dive
Eli Lilly Jun 8, 2026 Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising. - Barron's
Eli Lilly Jun 6, 2026 ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes - Fierce Biotech
Eli Lilly Jun 4, 2026 Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Stocktwits
Eli Lilly Jun 4, 2026 Pharmalittle: We're reading about fewer pharma investments in Germany, growing U.S. layoffs, and more - statnews.com
Eli Lilly Jun 4, 2026 Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership - Pharmaceutical Technology
Eli Lilly Jun 4, 2026 Eli Lilly forms billion-dollar genetic kidney disease partnership with US biotech Ascidian Therapeutics - medwatch.com